Deep Brain Stimulation

A 'pacemaker for the brain': implanted electrodes delivering continuous pulses to deep structures to treat Parkinson's disease, tremor, dystonia, epilepsy and OCD — how it was discovered, how it might work, and the new adaptive systems.

Discovery

For decades, surgeons treated severe tremor and Parkinson's disease by deliberately destroying small parts of the thalamus or basal ganglia (lesioning). During surgery, they tested targets with electrical stimulation. In 1987 the French neurosurgeon Alim-Louis Benabid and neurologist Pierre Pollak in Grenoble noticed that high-frequency stimulation of the thalamus suppressed tremor just as well as a lesion — and the effect was reversible and adjustable. They implanted electrodes for long-term stimulation instead of destroying tissue. Work in primates by Mahlon DeLong and others on the subthalamic nucleus led to targeting it for Parkinson's disease.

How it's done

Using MRI-guided surgery, often with the patient awake so effects can be tested, surgeons place thin leads into a target such as the subthalamic nucleus, the globus pallidus internus or the thalamus. Wires run under the skin to a pulse generator implanted below the collarbone, like a cardiac pacemaker. Neurologists then fine-tune stimulation settings over weeks to months.

Uses

In the US, the FDA approved DBS for essential tremor (1997), Parkinson's disease (2002), dystonia (under a humanitarian device exemption, 2003), obsessive-compulsive disorder (humanitarian exemption, 2009) and epilepsy (2018, targeting the anterior thalamus). Well over a hundred thousand people worldwide have received DBS. In Parkinson's, it can greatly reduce tremor, stiffness, slowness and medication-related dyskinesias, and allow lower drug doses, though it does not stop the disease progressing. It is being researched for depression, Tourette's syndrome, addiction and disorders of consciousness, with mixed results so far.

How does it work?

Despite decades of use, the mechanism is still debated. DBS was first thought to mimic a lesion by silencing the target, but it appears to act more like jamming abnormal signals — disrupting pathological rhythmic activity in basal ganglia circuits (such as exaggerated beta oscillations in Parkinson's) and affecting fibres passing near the electrode.

Adaptive DBS

Conventional DBS delivers stimulation continuously. Adaptive (closed-loop) DBS senses brain signals and adjusts stimulation in real time. In 2025 the US FDA approved the first adaptive DBS system for Parkinson's disease (Medtronic's BrainSense Adaptive DBS), which uses beta-band activity to adjust stimulation automatically.

Risks and ethics

Risks include bleeding, infection and hardware problems; stimulation can sometimes affect mood, speech or impulse control. Rare reports of personality changes have prompted ethical discussion about identity and consent.